1. Home
  2. IMXI vs OMER Comparison

IMXI vs OMER Comparison

Compare IMXI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

N/A

Current Price

$15.38

Market Cap

456.2M

Sector

Technology

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$8.83

Market Cap

628.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMXI
OMER
Founded
1994
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
456.2M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
IMXI
OMER
Price
$15.38
$8.83
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$16.67
$27.50
AVG Volume (30 Days)
230.7K
1.5M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$625,123,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.95
N/A
P/E Ratio
$11.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.58
$2.95
52 Week High
$22.30
$13.60

Technical Indicators

Market Signals
Indicator
IMXI
OMER
Relative Strength Index (RSI) 64.37 46.20
Support Level $15.35 $8.27
Resistance Level $15.51 $11.71
Average True Range (ATR) 0.07 0.72
MACD -0.01 -0.31
Stochastic Oscillator 63.23 17.04

Price Performance

Historical Comparison
IMXI
OMER

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: